Fig. 2

Immune and Expression Signatures and Response to Neoadjuvant Chemotherapy and Survival in TNBC. a The calculated score for 125 published gene expression signatures for 127 patients with data on response to neoadjuvant chemothrapy and distant metastasis-free survival (DMFS). Each signature is a point. The association of each signature with neoadjuvant chemotherapy response (pathologic complete response vs. RD) by simple linear regression (y-axis) and hazard ratio for each signature using DMFS (x-axis) are displayed. Signatures were grouped by phenotype (as previously described [7]), identified by color: proliferation signatures (red), immune signatures (blue), ER/HER2 signatures (green), mesenchymal signatures (orange), others (grey). Size of each point relates to the hazard ratio p-value for each signature. b The association of three representative signatures from each group (immune, proliferation, ER/HER2, mesenchymal) with the relative proportion of 22 inferred immune cell subsets via CIBERSORT across all samples with gene expression data (n = 453) are visualized using CorrPlot [26, 29].